Idorsia

Switzerland
Allschwil, Basel-Landschaft, Switzerland, 4123

Company profile

Idorsia company profile

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

Business identity

Contact email
[email protected]
Phone number
41 58 844 00 00
Operating status
Active
Company type
For Profit
Employee range
501-1,000 employees
Revenue range
$10M-$100M
Founded
2017-06-01, Month

Headquarters

Postal code
4123
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
9
Total equity funding
$1.5B
Last funding
Post IPO Equity / $82.1M / 2025-10-10
Last equity funding
Post IPO Equity / $82.1M
Investors
2
Lead investors
2
Founders
2
Articles
219
Exited on
2017-06-16

Founders and investors

Founders

Jean-Paul ClozelMartine Clozel

Lead investors

CARB-XJean-Paul Clozel

Investors

CARB-XJean-Paul Clozel